← Back to Search

Other

Active Arm, Zota Cohort 2 for Coronavirus (PROPEL Trial)

Phase 1
Waitlist Available
Research Sponsored by Effector Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 days
Awards & highlights

PROPEL Trial Summary

This trial is testing a new drug to see if it is safe and effective against mild or moderate cases of COVID-19.

Eligible Conditions
  • Coronavirus

PROPEL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety as assessed by the incidence of Treatment Emergent Adverse Events and Serious Adverse Events
Safety as assessed by the incidence of adverse events of special interest
Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1)
+2 more
Secondary outcome measures
Mean change in SARS-CoV-2 viral load;
Proportion of patients with SARS-CoV-2 viral load below the level of detectability;
The time to clinical resolution;
+2 more
Other outcome measures
Assessment and quantification of infectious virus
Change in the WHO 9-point ordinal scale for clinical improvement
Mean change in viral load in plasma
+4 more

PROPEL Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Active Arm, Zota Cohort 2Active Control1 Intervention
0.02 mg/kg zotatifin
Group II: Active Arm, Zota Cohort 3Active Control1 Intervention
0.035 mg/kg zotatifin
Group III: Active Arm, Zota Cohort 1Active Control1 Intervention
0.01 mg/kg zotatifin
Group IV: PlaceboPlacebo Group1 Intervention
5% dextrose injection, USP

Find a Location

Who is running the clinical trial?

Effector TherapeuticsLead Sponsor
9 Previous Clinical Trials
437 Total Patients Enrolled
Medpace, Inc.Industry Sponsor
94 Previous Clinical Trials
29,579 Total Patients Enrolled
Douglas Warner, MDStudy DirectorEFFECTOR Therapeutics, Inc.
2 Previous Clinical Trials
210 Total Patients Enrolled
~9 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top